Empowering strategies for emerging platform companies in the RNA field
Panel Discussion: Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities
At this year’s 2nd RNA-Targeted Drug Discovery Summit (December 2-4, Boston), an expert panel will take to the stage, giving you the opportunity to ask your questions to the leaders of the RNA community to build valuable strategies that will advance the translation of safe, targeted and robust RNA targeted small molecules into clinical trials.
Jane Withka, Director & Collaboration Lead, Pfizer Worldwide R&D, Yochi Slonim, Co-Founder & CEO, Anima Biotech, Kathryn McCabe, Sr Director of Business Development- Emerging Technology & Innovation, Eli Lilly, Jennifer Petter, Founder & CSO, Arrakis Therapeutics and Christopher Barbieri, Senior Investigator, Bristol-Myers Squibb will lead this this industry-led panel discussion.
Join us and discover:
- How to establish strategies & standards to provide clear guidance on how to intentionally target RNA with small molecules?
- How mRNA and its regulatory mechanisms can enable new strategies against previously undruggable targets? View of the right approach in this vast, novel target space.
- Partnering with pharma: the strategies for emerging platform companies in the RNA field for effective partnering
Register here and join the 2nd RNA- Targeted Drug Discovery Summit 2019 to hear five world-class leaders discuss these critical challenges and stay ahead of the curve.
You won’t be alone in signing up, 100+ key leaders from the likes of Biogen, Sanofi, Skyhawk Therapeutics, Remix Therapeutics, Twentyeight-Seven Therapeutics and many more are coming together in Boston this December to finally drug the undruggable RNA.